UPCC 38417: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
Enrolling By Invitation
99 years and younger
All
1 participants needed
1 Location
Brief description of study
TBD
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ['Lymphoma, B-Cell', 'Lymphoma, Non-Hodgkin', 'Leukemia, B-cell', 'Graft Vs Host Disease', 'Solid Tumor']
-
Age: - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 828236
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
